Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial
Copyright policy )Aspirin Discontinuation at 24 to 28 Weeks’ Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial
(JAMA. 2023;329:542–550) Globally, 70,000 maternal deaths and 500,000 fetal deaths each year can be attributed to preeclampsia, which affects roughly 2-4% of pregnancies. Diagnosis of preeclampsia falls into several categories depending on gestational age at diagnosis, with early-onset preeclampsia (delivery <34 wk), preterm preeclampsia (delivery <37 wk), and term preeclampsia (delivery at or past 37 wk). Many serious complications can be associated with a diagnosis of preeclampsia, including preterm birth, fetal growth restriction, placental abruption, seizures, and others, with earlier onset correlating with more severe complications. Previous research has identified aspirin as an effective way to reduce the incidence of preeclampsia in high-risk individuals, especially when treatment is initiated in the late first trimester or early second trimester.
- Autonomous University of Barcelona Spain
- Consorci Sanitari de Terrassa Spain
- Institut Català de la Salut Spain
- Comunidad de Madrid Spain
- Mútua Terrassa Spain
Adult, Embaràs, Hemorrhage, DISEASES::Female Urogenital Diseases and Pregnancy Complications::Pregnancy Complications::Hypertension, Pregnancy-Induced::Pre-Eclampsia, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, Preeclàmpsia, COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::hidrocarburos::hidrocarburos cíclicos::hidrocarburos aromáticos::derivados del benceno::fenoles::hidroxibenzoatos::salicilatos::aspirina, Pre-Eclampsia, Pregnancy, Peripartum Period, Humans, Other subheadings::Other subheadings::Other subheadings::/prevention & control, Aspirina, Placenta Growth Factor, Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control, Vascular Endothelial Growth Factor Receptor-1, SALUD PÚBLICA::salud ambiental::salud::enfermedad ambiental::complicaciones del embarazo, Aspirin, Infant, Newborn, ENFERMEDADES::enfermedades de los genitales femeninos y complicaciones del embarazo::complicaciones del embarazo::hipertensión inducida en el embarazo::preeclampsia, Pregnancy Complications, PUBLIC HEALTH::Environmental Health::Health::Environmental Illness::Pregnancy Complications, Pregnancy Trimester, First, CHEMICALS AND DRUGS::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenols::Hydroxybenzoates::Salicylates::Aspirin, Other subheadings::Other subheadings::Other subheadings::/adverse effects, Withholding Treatment, Premature Birth, Female, Biomarkers
Adult, Embaràs, Hemorrhage, DISEASES::Female Urogenital Diseases and Pregnancy Complications::Pregnancy Complications::Hypertension, Pregnancy-Induced::Pre-Eclampsia, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, Preeclàmpsia, COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::hidrocarburos::hidrocarburos cíclicos::hidrocarburos aromáticos::derivados del benceno::fenoles::hidroxibenzoatos::salicilatos::aspirina, Pre-Eclampsia, Pregnancy, Peripartum Period, Humans, Other subheadings::Other subheadings::Other subheadings::/prevention & control, Aspirina, Placenta Growth Factor, Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control, Vascular Endothelial Growth Factor Receptor-1, SALUD PÚBLICA::salud ambiental::salud::enfermedad ambiental::complicaciones del embarazo, Aspirin, Infant, Newborn, ENFERMEDADES::enfermedades de los genitales femeninos y complicaciones del embarazo::complicaciones del embarazo::hipertensión inducida en el embarazo::preeclampsia, Pregnancy Complications, PUBLIC HEALTH::Environmental Health::Health::Environmental Illness::Pregnancy Complications, Pregnancy Trimester, First, CHEMICALS AND DRUGS::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenols::Hydroxybenzoates::Salicylates::Aspirin, Other subheadings::Other subheadings::Other subheadings::/adverse effects, Withholding Treatment, Premature Birth, Female, Biomarkers
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).41 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!